Based on these findings, we speculate that the BCL-2-mediated ‘intrinsic’ apoptosis pathway might widely function in various aneurysmal diseases, promoting VSMCs phenotype switch, thus might be a novel therapeutic target for aneurysm prevention and treatment. Here, BCL2 is linked to aneurysm.